These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 12901947

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Gemtuzumab ozogamicin and targeted cancer therapy].
    Imaizumi M.
    Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
    [Abstract] [Full Text] [Related]

  • 23. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E.
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [Abstract] [Full Text] [Related]

  • 24. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S, Stasi R.
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [Abstract] [Full Text] [Related]

  • 25. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
    Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL.
    Blood; 2003 May 01; 101(9):3641-7. PubMed ID: 12511412
    [Abstract] [Full Text] [Related]

  • 26. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA, Foon KA.
    Expert Opin Biol Ther; 2005 Sep 01; 5(9):1225-43. PubMed ID: 16120052
    [Abstract] [Full Text] [Related]

  • 27. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA.
    Clin Lymphoma; 2002 Mar 01; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [Abstract] [Full Text] [Related]

  • 28. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
    Voutsadakis IA.
    Anticancer Drugs; 2002 Aug 01; 13(7):685-92. PubMed ID: 12187324
    [Abstract] [Full Text] [Related]

  • 29. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A, Finolezzi E, Anaclerico B, Calabrese E, Levi A, Trasarti S, Tafuri A.
    Clin Ter; 2005 Aug 01; 156(4):183-6. PubMed ID: 16342520
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. New developments in antibody therapy for acute myeloid leukemia.
    Tomblyn MR, Tallman MS.
    Semin Oncol; 2003 Aug 01; 30(4):502-8. PubMed ID: 12939719
    [Abstract] [Full Text] [Related]

  • 33. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B, Gerber HP, Sapra P.
    Mol Immunol; 2015 Oct 01; 67(2 Pt A):107-16. PubMed ID: 25304309
    [Abstract] [Full Text] [Related]

  • 34. Siglecs as targets for therapy in immune-cell-mediated disease.
    O'Reilly MK, Paulson JC.
    Trends Pharmacol Sci; 2009 May 01; 30(5):240-8. PubMed ID: 19359050
    [Abstract] [Full Text] [Related]

  • 35. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM, Morris CQ.
    Adv Ther; 2017 May 01; 34(5):1015-1035. PubMed ID: 28361465
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
    Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE, Goldenberg DM, Rybak SM.
    Crit Rev Oncol Hematol; 2001 May 01; 39(1-2):79-86. PubMed ID: 11418304
    [Abstract] [Full Text] [Related]

  • 39. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K.
    Oncol Nurs Forum; 2002 May 01; 29(4):E52-9. PubMed ID: 12011919
    [Abstract] [Full Text] [Related]

  • 40. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L, Ball ED.
    Leukemia; 2006 Dec 01; 20(12):2093-101. PubMed ID: 17051243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.